IPO-bound Glenmark Life Sciences to focus on complex bulk drugs, contract business to drive growth

The company plans to develop eight to 10 molecules each year including high-value and high-volume APIs. It is looking at participating in the government’s production-linked incentive scheme.
( read original story …)


Search your Hotel